文献速递结核与非结核分枝杆菌

2000-17年135个中低收入国家结核病总支出追踪:按来源与功能分析的财务模型研究

Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000-17: a financial modelling study.
PubMed 文献 · Lancet Infect Dis · 2020-04-23

该财务模型研究估算了2000-17年135个中低收入国家结核病总支出,按来源(政府、个人自付、预付私人、发展援助)和功能(通报与非通报病例)分类。

核心结论

  • 尽管自2000年以来结核病资金大幅增加,但仍远低于全球融资目标,且资源受限国家个人自付支出仍高,构成患者获得诊疗和坚持治疗的障碍。
  • 30个高结核病负担国家中,略过半以政府出资为主,其余(尤其中低收入和低收入国家)仍主要依赖结核病发展援助或个人自付医疗支出。

研究设计与样本

  • 财务模型研究,从WHO全球结核病数据库、全球基金提案与报告、国民健康账户、WHO-CHOICE项目数据库及IHME发展援助健康数据库提取结核病支出、单位成本和医疗利用数据。
  • 覆盖全部135个中低收入国家(采用世界银行2019年定义),分别估算通报和未通报结核病例的支出,使用时空高斯过程回归填补缺失数据并估计不确定性。
  • 汇总政府、个人自付、预付私人和发展援助支出,以2019年美元估算总支出。

临床怎么用

  • 提示临床医生在资源受限国家应关注结核病患者的个人自付负担,其可能影响诊疗可及性和治疗依从性。
  • 高结核病负担国家中部分仍主要依赖发展援助或个人自付,临床实践中需考虑患者经济障碍对治疗持续性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Estimates of government spending and development assistance for tuberculosis exist, but less is known about out-of-pocket and prepaid private spending. We aimed to provide comprehensive estimates of total spending on tuberculosis in low-income and middle-income countries for 2000-17. METHODS: We extracted data on tuberculosis spending, unit costs, and health-care use from the WHO global tuberculosis database, Global Fund proposals and reports, National Health Accounts, the WHO-Choosing Interventions that are Cost-Effective project database, and the Institute for Health Metrics and Evaluation Development Assistance for Health Database. We extracted data from at least one of these sources for all 135 low-income and middle-income countries using the World Bank 2019 definitions. We estimated tuberculosis spending by source and function for notified (officially reported) and non-notified tuberculosis cases separately and combined, using spatiotemporal Gaussian process regression to fill in for missing data and estimate uncertainty. We aggregated estimates of government, out-of-pocket, prepaid private, and development assistance spending on tuberculosis to estimate total spending in 2019 US$. FINDINGS: Total spending on tuberculosis in 135 low-income and middle-income countries increased annually by 3·9% (95% CI 3·0 to 4·6), from $5·7 billion (5·2 to 6·5) in 2000 to $10·9 billion (10·3 to 11·8) in 2017. Government spending increased annually by 5·1% (4·4 to 5·7) between 2000 and 2017, and reached $6·9 billion (6·5 to 7·5) or 63·5% (59·2 to 66·8) of all tuberculosis spending in 2017. Of government spending, $5·8 billion (5·6 to 6·1) was spent on notified cases. Out-of-pocket spending decreased annually by 0·8% (-2·9 to 1·3), from $2·4 billion (1·9 to 3·1) in 2000 to $2·1 billion (1·6 to 2·7) in 2017. Development assistance for country-specific spending on tuberculosis increased from $54·6 million in 2000 to $1·1 billion in 2017. Administrative costs and development assistance for global projects related to tuberculosis care increased from $85·3 million in 2000 to $576·2 million in 2017. 30 high tuberculosis burden countries of low and middle income accounted for 73·7% (71·8-75·8) of tuberculosis spending in 2017. INTERPRETATION: Despite substantial increases since 2000, funding for tuberculosis is still far short of global financing targets and out-of-pocket spending remains high in resource-constrained countries, posing a barrier to patient's access to care and treatment adherence. Of the 30 countries with a high-burden of tuberculosis, just over half were primarily funded by government, while others, especially lower-middle-income and low-income countries, were still primarily dependent on development assistance for tuberculosis or out-of-pocket health spending. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Su Y, Garcia Baena I, Harle AC, et al. Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000-17: a financial modelling study. Lancet Infect Dis. 2020. PMID: 32334658. doi:10.1016/S1473-3099(20)30124-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。